PDCD1 and neoplasm: Additionally, AC484 increased TCR diversity within tumors; it led to a proinflammatory tumor microenvironment supportive of antitumor immunity, which is inconsistent with the tumor microenvironment induced by anti‐PD‐1 inhibitors.